Fig. 5

rWTC-MBTA vaccine enhances antigen presentation by increasing the proportion of antigen-presenting cells. After one or multi-dose treatments, lymph nodes (LNs) were collected to check the percentage of APCs by flow cytometry. a, Schematic diagram of the experimental design. b, Percentage of dendritic cells. c, Percentage of monocytes. d, Percentage of B cells. e, Percentage of mature DCs (gated as CD80⁺CD86⁺) after one or multi-dose of treatments. f, Percentage of MHCII⁺ monocytes in total monocytes after one or multi-dose treatments. g, CD137L⁺ B cells in total B cells after one or multi-dose treatments (gated on CD45 + cells). h, Serum concentrations of IFN-γ and i, IL-6 after one or multi-dose treatments. Ordinary one-way ANOVA with multiple comparisons was used to assess statistical significance. All data are represented as mean ± SD. P-values shown for each treated group compared to the rWTC-MBTA vaccine group (n = 5/group). *P < 0.05, **P < 0.01, ***P < 0.001, **** P < 0.0001